Psoriasis Drugs Market Size, Share, Growth and Forecast, 2025-2035

Interleukin biologics anchor psoriasis spending

The global psoriasis drugs market was valued at USD 20.50 billion in 2025 and is projected to increase from USD 21.54 billion in 2026 to USD 33.62 billion by 2035, registering a CAGR of 5.07% during 2026–2035. Demand comes from adults and children with moderate-to-severe plaque psoriasis who need long-term systemic therapy, from patients with psoriatic arthritis and from the much larger group treated with topical products. North America held the largest regional share, 46.0% in 2025, because the United States has the highest biologic use and prices. Asia Pacific is the fastest-growing region at 6.44% a year, as China, Japan and India widen specialist care and reimbursement for advanced therapy. The commercial picture shifted after January 2025, when lower-cost ustekinumab biosimilars reached U.S. pharmacies, and again in March 2026, when U.S. regulators approved the first oral peptide that blocks the IL-23 receptor. As a result, growth now depends on how quickly pills and biosimilars change prescribing habits.

Which psoriasis medicines does this analysis count?

The analysis counts prescription medicines used to treat plaque, pustular and other forms of psoriasis, including interleukin inhibitors, TNF alfa inhibitors, oral anti-inflammatory small molecules, corticosteroids and glucocorticoids. Dermatologists, rheumatologists and primary care physicians prescribe these products, which patients obtain through hospital, retail, specialty and online pharmacies.

Phototherapy equipment, laser procedures, cosmetic skin care and over-the-counter emollients sit outside the value counted here. The value chain runs from originator and biosimilar manufacturers through wholesalers and specialty distributors to pharmacies, payers and patients, with rebates and tenders shaping the net price paid in each region.

Interleukin inhibitors and injections lead spending

Why do interleukin inhibitors lead drug classes?

Based on drug class, the market is categorized into interleukin inhibitors, corticosteroids, anti-inflammatory drugs, glucocorticoids, TNF alfa inhibitors and others. Interleukin Inhibitors led with a 42.0% share of 2025 value, because IL-17 and IL-23 blockers clear skin in most treated patients. This class also grows fastest at 6.38% a year, as new approvals add indications and patients. In contrast, TNF alfa inhibitors grow slowly as biosimilars cut prices.

How fast are oral therapies gaining on injections?

Based on route of administration, the market is categorized into oral, injection and others, which covers topical products. Injection led with a 70.0% share of 2025 value, because most biologics are given under the skin every few weeks or months. Oral therapies grow fastest at 6.62% a year, as targeted pills offer high clearance rates without injections.

Which pharmacy channels dispense the most value?

Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, online pharmacy and others. Retail Pharmacy led with a 44.0% share of 2025 value, because specialty and community pharmacies dispense most self-injected biologics and topical refills. Online Pharmacy grows fastest at 7.14% a year, as mail-order specialty services and home delivery spread across several regions.

Large patient pools and new approvals lift demand

How does the size of the patient pool sustain demand?

The size of the patient pool is the main demand driver, because psoriasis is a lifelong disease that needs continuous treatment. The World Health Organization reports that psoriasis affects approximately 100 million people worldwide. In the United States alone, the National Psoriasis Foundation counts more than 8 million people living with the disease, and it cites a broader estimate of 125 million people, or 2% to 3% of the world population. The foundation also says nearly one-quarter of patients have moderate-to-severe disease, the group that usually needs systemic therapy. As a result, each newly diagnosed patient adds recurring demand over many years of follow-up care rather than a single course of treatment.

Why does psoriatic arthritis widen systemic treatment?

Psoriatic arthritis widens systemic treatment, because joint disease requires drugs that act on the whole body rather than creams. The WHO reports that between 1.3% and 34.7% of people with psoriasis develop chronic inflammatory arthritis. Sun Pharma states that about 1 in 3 people with psoriasis develop the condition and that up to 2.4 million Americans live with it. In September 2024, UCB received U.S. approval for Bimzelx in active psoriatic arthritis, adding to its October 2023 plaque psoriasis approval. In turn, psoriatic arthritis treatment choices increasingly overlap with skin therapy, which lifts spending per patient in rheumatology clinics.

Download Free Sample

How are new approvals adding treated patients?

New approvals add treated patients, because each new mechanism gives physicians another option after earlier drugs lose effect. In March 2026, the FDA approved icotrokinra from Johnson & Johnson for moderate-to-severe plaque psoriasis in adults and in patients aged 12 and older. In the ICONIC-ADVANCE trials, about 70% of patients reached clear or almost clear skin at week 16, and 55% reached PASI 90. In March 2024, the FDA also expanded Spevigo from Boehringer Ingelheim to generalized pustular psoriasis in patients 12 and older weighing at least 40 kg. These decisions support interleukin inhibitors, which held 42.0% of 2025 value across all drug classes.

Why are pediatric and early treatment lifting volumes?

Pediatric and early treatment lift volumes, because labels now reach patients long before they are adults. Icotrokinra gained its first U.S. approval for adults and adolescents aged 12 and older, giving teenagers a pill instead of injections. Selarsdi from Teva and Alvotech was approved in April 2024 for plaque psoriasis and psoriatic arthritis in patients aged 6 and older. Spevigo is also cleared for patients aged 12 and older with generalized pustular psoriasis, a rare and severe form. Because these patients may stay on therapy for decades, oral drugs that avoid needles gain a long runway in younger age groups. As a result, pediatric dermatology clinics become a steady source of new starts.

Oral targeted pills and biosimilars reshape care

How is the rise of oral targeted pills changing care?

A rise in oral targeted pills is changing care, because many patients prefer tablets to regular injections. In December 2025, Takeda reported Phase 3 results for zasocitinib, a once-daily TYK2 inhibitor, from two LATITUDE studies with 693 and 1,108 patients across 21 countries. More than half of patients reached PASI 90 by week 16, and about 30% reached completely clear skin. Takeda plans to file with the FDA and other regulators starting in fiscal year 2026. Icotrokinra beat deucravacitinib in head-to-head trials, which shows that rival pills now compete on efficacy. In turn, oral therapies grow at 6.62% a year, faster than injections.

Is the shift to ustekinumab biosimilars cutting costs?

The shift to ustekinumab biosimilars is cutting costs, because payers now steer new patients toward lower-priced versions. Amgen launched Wezlana on Jan. 1, 2025, as the first U.S. biosimilar referencing Stelara. Seven ustekinumab biosimilars, including Selarsdi, Pyzchiva, Otulfi, Imuldosa, Yesintek and Steqeyma, were expected on the U.S. market during 2025, giving payers several competing suppliers. Celltrion won approval for Steqeyma at the end of December 2024, adding another supplier. Because biosimilars lower the price of established biologics, TNF alfa and older interleukin products lose value even as patient numbers rise. As a result, originators work to move patients toward newer interleukin and oral drugs with patent protection.

Download Free Sample

Where can psoriatic arthritis labels open new revenue?

Psoriatic arthritis labels open a clear opportunity, because drugs approved for both skin and joints win more prescriptions. In March 2026, Sun Pharma said the FDA accepted its application to extend Ilumya to adults with active psoriatic arthritis, with a decision expected by Oct. 29, 2026. The filing rests on the INSPIRE-1 and INSPIRE-2 Phase 3 trials, each lasting 52 weeks. Sun Pharma also notes that more than 15% of people with psoriasis may have undiagnosed joint disease. In turn, interleukin inhibitors that cover both conditions can expand use in shared dermatology and rheumatology care, where patients often need one drug that treats both skin plaques and painful joints.

Can Asia Pacific access programs create new demand?

Asia Pacific access programs create a growth opening, because many patients in the region still rely on older topical and systemic drugs. The WHO estimates about 100 million people live with psoriasis worldwide, and most live outside North America and Europe. World Bank data show health spending of about USD 881 per person in East Asia and Pacific in 2023, against about USD 12,699 in North America. This gap leaves room for biosimilars and lower-priced pills to reach new patients. Because of this, Asia Pacific grows at the fastest pace of any region, as local manufacturers and reimbursement listings widen access to biologics.

Price pressure and access gaps slow growth

How do Medicare negotiated prices pressure revenue?

Medicare negotiated prices pressure revenue, because older patients account for a large share of U.S. biologic use. The Centers for Medicare & Medicaid Services set negotiated prices for Stelara and Enbrel that took effect on Jan. 1, 2026. Otezla, an oral psoriasis drug, is in the second negotiation cycle, with prices effective Jan. 1, 2027. As a result, manufacturers face lower net prices for established products and must rely on newer therapies for growth.

Why does biosimilar erosion cut older product sales?

Biosimilar erosion cuts older product sales, because pharmacy benefit managers favor lower-cost versions on formularies. Seven ustekinumab biosimilars now compete with Stelara in the United States, and TNF alfa biosimilars already compete in many countries. CMS also removed Stelara from its selected drug list effective Jan. 1, 2027, after biosimilar entry. In turn, TNF alfa inhibitors grow far slower than the market, which drags on total value through 2035.

Do access gaps leave patients undertreated?

Access gaps leave many patients undertreated, because advanced therapy is costly and specialists are scarce in low-income regions. The WHO has urged countries to improve access to and affordability of essential psoriasis medicines and to train primary care workers. World Bank data show health spending of about USD 79 per person in Sub-Saharan Africa in 2023. As a result, many patients there still receive only topical corticosteroids or no treatment at all.

Can safety screening slow treatment starts?

Safety screening can slow treatment starts, because most systemic drugs require tests before the first dose. Clinical reporting on the icotrokinra approval recommends tuberculosis screening before treatment, as is common for biologics. Patients may wait weeks for screening results and payer approval, and some stop before starting therapy. However, simpler oral regimens and better coordination between clinics and specialty pharmacies can shorten that delay considerably.

U.S. biologic use keeps North America ahead

How does U.S. biologic use keep North America ahead?

North America held a 46.0% share of 2025 value and grows at 4.74% a year through 2035. The United States has more than 8 million people with psoriasis, and many receive interleukin inhibitors early in care. However, ustekinumab biosimilars launched from January 2025 and Medicare negotiated prices from January 2026 lower net prices for older brands. As a result, U.S. growth depends on new pills such as icotrokinra and on psoriatic arthritis labels.

What makes Asia Pacific the fastest-growing region?

Asia Pacific held a 17.0% share of 2025 value and is the fastest-growing region at 6.44% a year. Japan has a mature biologic market, while China and India are adding reimbursement for advanced therapies. Sun Pharma, based in India and Takeda, based in Japan, both develop psoriasis therapies with global reach. Because health spending per person remains low in much of the region, biosimilars and pills drive most new patient starts.

Download Free Sample

Why does Europe grow slower than other regions?

Europe held a 27.0% share of 2025 value and grows at 4.44% a year, the slowest pace of the five regions. National health systems use tenders and biosimilar switching to keep biologic prices low. LEO Pharma, Novartis, Sanofi and UCB run major dermatology and immunology businesses in Europe. However, guideline-driven care means many eligible patients do receive interleukin inhibitors once older drugs stop working.

How are Latin American payers shaping demand?

Latin America held a 6.0% share of 2025 value and grows at 5.84% a year through 2035. Public payers in Brazil, Mexico and Argentina buy biologics through tenders that reward low prices. As a result, biosimilars gain share quickly, while private clinics adopt newer interleukin inhibitors for insured patients.

Where do the Middle East and Africa source therapy?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 5.74% a year through 2035. Gulf hospitals import originator biologics, while much of Africa relies on topical corticosteroids and older oral drugs because specialist care is limited.

Download Free Sample

Approvals and launches since 2024

Drug mechanisms and formats to watch

• Oral IL-23 receptor peptides block the same pathway as injected IL-23 antibodies, as icotrokinra does in a daily pill that patients can take at home without injection training.
• TYK2 inhibitors interrupt cytokine signals inside immune cells, with zasocitinib showing PASI 90 in more than half of patients across two large Phase 3 trials.
• Dual IL-17A and IL-17F blockade targets two related cytokines at once, as bimekizumab does with dosing every four weeks in both skin and joint disease.
• IL-36 receptor antibodies treat generalized pustular psoriasis flares, as spesolimab does with an infusion during flares and injections between flares.

Biologic makers defend share as pills arrive

Rivalry in psoriasis therapy turns on clinical results, dosing convenience and net price, because payers now have many interchangeable options. AbbVie, Johnson & Johnson, Novartis, Eli Lilly and UCB compete with interleukin inhibitors that clear skin in most patients. Johnson & Johnson added the first oral IL-23 receptor peptide in March 2026, while Takeda prepares filings for zasocitinib. Amgen sells both a Stelara biosimilar and oral therapy, and Pfizer, Merck and AstraZeneca hold immunology portfolios and pipelines. Boehringer Ingelheim targets the rare pustular form, and Sun Pharma seeks a psoriatic arthritis label for Ilumya. LEO Pharma and Sanofi focus on dermatology care, while Celgene heritage products still shape oral treatment. Each company now defends share against biosimilars by adding indications and patient support programs.

Companies profiled and their roles in this market

Oral entrants and biosimilars set the pace to 2035

Credence Research expects oral entrants and biosimilars, rather than new patient numbers alone, to set the pace of growth through 2035. The market advances at 5.07% a year, as interleukin inhibitors keep the lead and oral pills gain ground quickly. Icotrokinra and zasocitinib give patients injection-free options with high clearance rates, while seven ustekinumab biosimilars lower the price of an established biologic. Companies with both skin and joint labels should defend share best, while makers of older TNF alfa inhibitors face steady price erosion from tenders and negotiated prices.

How Credence Research sized psoriasis drug spending

The base year is 2025 and the forecast runs from 2026 to 2035. Market values come from the Credence Research model, which sums spending by drug class, route of administration and distribution channel across five regions. Splits by region and segment are Credence Research estimates, informed by World Health Organization and National Psoriasis Foundation disease data, World Bank health spending data, FDA and CMS decisions and company releases. This edition relies on published sources only and did not use primary interviews or surveys.

Psoriasis treatment outlook to 2035

The psoriasis drugs market is projected to reach USD 33.62 billion by 2035, with interleukin inhibitors and oral therapies supplying most of the added value. Biosimilars will keep lowering the price of older biologics, while new pills widen treatment for patients who avoid injections. North America keeps the highest spending per patient, and Asia Pacific adds the largest number of new treated patients. Psoriatic arthritis labels, pediatric approvals and online pharmacy delivery should widen use further. As a result, clinical data and net price will separate leaders from followers over the decade.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.